Wall Street can be surprisingly stubborn at times. Right now, for instance, it appears that there's a deep commitment to like Abbott Labs as a recovery play in 2014, but an equal commitment to dump on Baxter (NYSE: BAX ) and predict significant market share loss to Biogen Idec (NASDAQ: BIIB ) in hemophilia coupled with other imagined disappointments.
To be sure, Baxter is not my favorite stock today, and the company
did not provide a perfectly clean fourth quarter on Thursday morning.
What Baxter did offer, however, was good enough; I think investors who
can be patient with a pretty understated company can do well over the
long term with Baxter.
Read the full article here:
Baxter International, Inc. Will Be Nit-Picked, but The Quality Is There
No comments:
Post a Comment